These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 23113827

  • 1. Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia.
    Cortoos PJ, Gilissen C, Laekeman G, Peetermans WE, Leenaers H, Vandorpe L, Simoens S.
    Scand J Infect Dis; 2013 Mar; 45(3):219-26. PubMed ID: 23113827
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M, Schein J, Mody S, Grant R, Benson C, Olson W.
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [Abstract] [Full Text] [Related]

  • 4. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
    Bertrán MJ, Trilla A, Codina C, Carné X, Ribas J, Asenjo MA.
    Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
    [Abstract] [Full Text] [Related]

  • 5. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H, Song X, Crespi S, Navaratnam P.
    Value Health; 2009 Nov; 12(8):1135-43. PubMed ID: 19695010
    [Abstract] [Full Text] [Related]

  • 6. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 7. Potential for cost-savings in the care of hospitalized low-risk community-acquired pneumonia patients in China.
    Zhou QT, He B, Zhu H.
    Value Health; 2009 Mar; 12(1):40-6. PubMed ID: 18637052
    [Abstract] [Full Text] [Related]

  • 8. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR, Attridge RT, Mortensen EM, Restrepo MI, Yu Y, Oramasionwu CU, Ruiz JL, Burgess DS.
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [Abstract] [Full Text] [Related]

  • 9. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
    Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D.
    Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
    [Abstract] [Full Text] [Related]

  • 10. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis.
    Ott SR, Hauptmeier BM, Ernen C, Lepper PM, Nüesch E, Pletz MW, Hecht J, Welte T, Bauer TT.
    Eur Respir J; 2012 Mar; 39(3):611-8. PubMed ID: 21965229
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
    Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG.
    Arch Intern Med; 2004 Mar 22; 164(6):637-44. PubMed ID: 15037492
    [Abstract] [Full Text] [Related]

  • 15. Pharmaceutical industry research and cost savings in community-acquired pneumonia.
    Kessler LA, Waterer GW, Barca R, Wunderink RG.
    Am J Manag Care; 2002 Sep 22; 8(9):798-800. PubMed ID: 12234020
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia.
    Lee RW, Lindstrom ST.
    Respirology; 2007 Sep 22; 12(5):754-8. PubMed ID: 17875067
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
    Marras TK, Nopmaneejumruslers C, Chan CK.
    Am J Med; 2004 Mar 15; 116(6):385-93. PubMed ID: 15006587
    [Abstract] [Full Text] [Related]

  • 19. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia.
    Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL.
    Pharmacotherapy; 2010 May 15; 30(5):453-62. PubMed ID: 20411997
    [Abstract] [Full Text] [Related]

  • 20. Reducing door-to-antibiotic time in community-acquired pneumonia: Controlled before-and-after evaluation and cost-effectiveness analysis.
    Barlow G, Nathwani D, Williams F, Ogston S, Winter J, Jones M, Slane P, Myers E, Sullivan F, Stevens N, Duffey R, Lowden K, Davey P.
    Thorax; 2007 Jan 15; 62(1):67-74. PubMed ID: 16928714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.